CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 55 enrolled
Drug / intervention
AT-101 +3 moredrug
Likely dose
AT-101 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01633541
NCT01633541Phase 2Completed
CompareCT.gov

Concomitant Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Bio-selection For Organ Preservation In Patients With Advanced Laryngeal Cancer

University of Michigan Rogel Cancer Center·interventional·Posted Jul 4, 2012·Updated Jul 20, 2023

In Brief

A Phase 2 clinical trial evaluating AT-101, Docetaxel, and 2 other interventions for Laryngeal Cancer. Completed, enrolled 55 participants across 1 site.

Detailed Summary

To evaluate a new treatment approach for adults with advanced laryngeal cancer: induction chemotherapy with platinum and docetaxel plus AT-101. AT-101 is an investigational drug for the treatment of advanced cancer. It is hoped that the combination of this chemotherapy regimen will allow cancer patients to keep their voice box and to improve/maintain voice-related quality of life. The ultimate goal of this study is to prevent the surgery to remove subjects voice box.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLaryngeal Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 4, 2012
Enrollment StartMar 1, 2012
Primary CompletionNov 6, 2021
TodayJul 2, 2026
Enrollment to primary: 9.7 yearsPosted 14.0 years ago

Interventions

AT-101drug

Patients will receive AT-101 40 mg orally two times a day.

Docetaxeldrug

Docetaxel (Taxotere) 75 mg/m2

Cisplatindrug

Cisplatin 100 mg/m2

Carboplatindrug

Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg